Analysis of price and access to azatilimab (axatilimab-csfr)

Azatilimab(axatilimab-csfr, trade nameNIKTIMVO™) as an innovative colony-stimulating factor -1Receptor (CSF-1R) inhibitors bring new hope to patients with chronic graft-versus-host disease (cGVHD). cGVHD is a serious complication after allogeneic stem cell transplantation. It is caused by the patient's immune system rejecting the donated stem cells and attacking their own tissues and organs.

Azatilizumab effectively reduces inflammation and fibrosis by blocking the CSF-1R signaling pathway, and significantly improves the symptoms of cGVHD patients. The drug is suitable for adult and pediatric patients weighing no less than 40 kilograms, especially those who have failed to respond after at least two systemic treatments and are in urgent need of new treatment options.

During treatment, azatilizumab is given by intravenous infusion every two weeks, with each infusion lasting approximately 30 minutes. To ensure patient safety, healthcare providers often prescribe prophylactic medications such as diphenhydramine (anti-allergy medication) and acetaminophen (fever-reducing medication) before infusion to reduce the risk of infusion reactions.

Clinical trial results show that azatilizumab has demonstrated excellent efficacy in the treatment of cGVHD, with an overall response rate as high as 75% and a long-lasting and stable efficacy. However, along with its significant efficacy, there may also be a range of side effects, including muscle and joint pain, fatigue, increased risk of infection, nausea, headache, diarrhea, cough, fever and difficulty breathing. In addition, laboratory tests may also reveal abnormalities such as increased liver function indicators and decreased hemoglobin levels.

It is important to note that azatilizumab is embryo-fetotoxic and may cause potential harm to the fetus. Therefore, women of childbearing potential must take effective contraceptive measures during treatment and within 30 days after stopping treatment. At the same time, breastfeeding women should also avoid using this drug.

Azatilizumab, as a new player in the cGVHD treatment field, provides patients with more treatment options. However, its use must strictly follow the guidance of medical professionals to ensure the safety and effectiveness of the treatment. Because azatilizumab has just been approved by the USFDAApproved new drugs are currently difficult to purchase directly on the market.

For patients who are interested in learning about or obtaining azatilizumab, it is recommended that they consult and learn more through regular overseas medical consulting companies. These professional institutions can provide the latest drug information, purchasing channels and related medical consulting services to help patients better understand and obtain this innovative treatment drug.

Reference link:https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-niktimvo